Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Biology

Background:

• First-generation epidermal growth factor receptor (EGFR) kinase inhibitors are effective against activating mutants in non-small cell lung cancer (NSCLC).
• Acquired resistance, often due to gatekeeper mutations like T790M, limits the duration of clinical responses to 8-14 months.
• There is a critical need for agents targeting common double mutants, such as T790M/L858R and T790M/del(746-750).

Purpose of the Study:

• To optimize a noncovalent, double mutant-selective lead compound for EGFR resistance mutations.
• To develop novel agents capable of overcoming acquired resistance in NSCLC.
• To identify compounds with high selectivity for T790M mutant EGFR over wild-type EGFR.

Main Methods:

• Structure-guided drug design and iterative synthesis.
• Optimization strategy focused on increasing potency without increasing lipophilicity or reducing 3D character.
• In vitro enzyme and cell-based assays to assess selectivity and potency.
• In vivo xenograft models to evaluate pathway knockdown.

Main Results:

• Cis-fluoro substitution on piperidinyl groups led to synergistic and substantial potency gains.
• These substitutions enhanced potency through direct enzyme interaction or effects on the ligand oxygen atom.
• A specific fluorohydroxypiperidine series yielded diastereomers with 50-fold selectivity for T790M mutants over wild-type EGFR.
• Demonstrated pathway knockdown in an in vivo xenograft model.

Conclusions:

• Optimized noncovalent inhibitors demonstrate significant selectivity for T790M mutant EGFR.
• The developed compounds represent promising candidates for treating NSCLC with acquired resistance.
• Structure-based design incorporating specific fluorine substitutions is an effective strategy for overcoming EGFR inhibitor resistance.